Immune Reconstitution Is Comparable in Antiretroviral-Naive Subjects after 1 Year of Successful Therapy with a Nucleoside Reverse-Transcriptase Inhibitor- or Protease Inhibitor-Containing Antiretroviral Regimen

Journal of Infectious Diseases

Volumn 188, Issue 10, 2003, Pages 1444-1454

  Landay, Alan L ^a   Spritzler, John ^b   Kessler, Harold ^a   Mildvan, Donna ^d   Pu, Minya ^b   Fox, Larry ^f   O'Neil, Dorothy ^g   Schock, Barbara ^e   Kuritzkes, Daniel ^c   Lederman, Michael M ^h  

^a RUSH MEDICAL COLLEGE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; ENZYME INHIBITION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INHIBITION KINETICS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PRIORITY JOURNAL; PROTEINASE INHIBITION; SKIN TEST; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS REPLICATION;

ADULT; AGED; APOPTOSIS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 10744229823     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379041     Document Type: Article

References (54)

1. Palella FJ, Delaney KM, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus syndrome. N Engl J Med 1998; 338:853-60.
2. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333:1528-33.
3. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
4. Kelleher AD, Carr A, Zaunders J, et al. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173:321-9.
5. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
6. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998; 177:898-904.
7. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000; 181:358-63.
8. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-14.
9. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-8.
10. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690-5.
11. Smith KY, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000; 181:141-7.
12. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999; 73:797-800.
13. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group protocol 315. J Infect Dis 1998; 178:70-9.
14. Al-Harthi L, Siegel J, Spritzler J, et al. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 2000; 14:761-70.
15. Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999; 180:1050-6.
16. Aukrust P, Muller F, Lien E, et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999; 179:74-82.
17. Rinaldo CR Jr, Liebmann JM, Huang XL, et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999; 179:329-36.
18. Angel JB, Parato KG, Kumar A, et al. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. J Infect Dis 2001; 183:546-54.
19. Blankson JN, Gallant JE, Siliciano RF. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis 2001; 183:657-61.
20. Pontesilli O, Kerkhof-Garde S, Notermans DW, et al. Functional T cell reconstitution and human immunodeficiency virus type 1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999; 180:76-86.
21. Plana M, Garcia F, Gallart T, et al. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Lancet 1998; 352:1194-5.
22. Kelleher AD, Carr A, Zaunders J, et al. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173:321-9.
23. Badley AD, Pilon AA, Landay A, et al. Mechanisms of HIV associated lymphocyte apoptosis. Blood 2000; 96:2951-64.
24. Phenix BN, Angel JB, Mandy F, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:559-67.
25. + T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999; 94:1021-7.
26. Badley AD, Parato K, Cameron DWS, et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999; 6:420-32.
27. Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998; 102:79-87.
28. Kaufmann D, Pantaleo G, Sudre P, et al. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351:723-4.
29. + cell counts despite persistently detectable HIV load. N Engl J Med 1998; 338:1074-5.
30. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-53.
31. + T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001; 183:1009-16.
32. Piketty C, Weiss L, Thomas F, et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328-35.
33. + T-cell death. J Virol 2002; 76:5966-73.
34. - cells. Blood 2000; 96:2735-9.
35. Strack P, West M, Rizzo C, et al. Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Proc Natl Acad Sci USA 1996; 93:9571-6.
36. AIDS Clinical Trials Group Immunology Laboratory Committee consensus methodologies. Bethesda, MD: National Institutes of Health, 1997; available at: http://aactg.s-3.com (accessed 5 November 2003).
37. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1-8.
38. Patki AH, Purvis SF, Valdez H, et al. HIV infection perturbs DNA content of lymphoid cells: partial correction after "suppression" of virus replication. AIDS 1999; 13:1177-85.
39. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. AIDS Clinical Trials Group 375 team. AIDS 2000; 14:11-21.
40. Sokal JE. Measurement of delayed skin-test responses. N Engl J Med 1975; 293:501-2.
41. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83-92.
42. Giorgi JV, Hultin LE, McKeating JA. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-70.
43. + T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 1998; 178:1279-87.
44. Carbone J, Gil J, Benito JM, et al. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 2000; 14:2823-9.
45. Leng Q, Borkow G, Weisman Z, et al. Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J Acquir Immune Defic Syndr 2001; 27:389-97.
46. Lange CG, Lederman MM, Medvik K, et al. Functional immune reconstitution is impaired when initiation of HAART is delayed in chronic HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol (in press).
47. Chavan SJ, Tamma SL, Kaplan M, et al. Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy. Clin Immunol 1999; 93:24-33.
48. + T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses 1999; 15:1509-18.
49. de Mendoza C, Soriano V, Rodriguez-Rosado R, et al. Higher antiviral activity of antiretroviral regimens including protease inhibitors. AIDS 1999; 13:998-9.
50. + cell counts after successful virologic suppression. Clin Infect Dis 2002; 35:1005-9.
51. Hirsch M, Steigbigel R, Staszewski S, et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis 1999; 180:659-65.
52. Kravcik S, Magill A, Sanghvi B, et al. Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure. HIV Clinical Trials 2001; 2:160-70.
53. Wu H, Kuritzkes DR, McClernon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points J Infect Dis 1999; 179:799-807.
54. Barreiro P, Soriano V, Casas E, et al. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002; 16:245-9.